The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

New Phase 2 Paid Hepatitis C Clinical Trial

Back to News Homepage

Next

Urgent Reason for Hep C Patients to Get Lean!

Gilead’s Sofosbuvir Gets High Marks for HIV/HCV Co-Infection

September 17, 2012

Print this page

Although those co-infected with Hepatitis C and HIV generally have a poorer prognosis and are harder to treat than those with mono-infection, the experimental Hepatitis C drug, sofosbuvir, appears to improve the outlook of this common dual infection.

Sofosbuvir appears safe and effective for HIV/HCV co-infected people

Liz Highleyman

Produced in collaboration with hivandhepatitis.com

Published: 13 September 2012

HIV/HCV co-infected people taking the experimental hepatitis C virus polymerase inhibitor sofosbuvir (formerly GS-7977) experienced a rapid decline in HCV viral load similar to that seen in HIV-negative patients, researchers reported on Wednesday at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. Side-effects were also similar and there was no sign of interactions with antiretroviral drugs in this 14-day study.

HIV-positive people with hepatitis C tend to experience more rapid liver disease progression than HIV-negative individuals and do not respond as well to interferon-based treatment. Adding new direct-acting anti-HCV drugs can improve response, but raises concerns about worsened side-effects and interactions with anti-HIV drugs. Furthermore, many co-infected people are considered ineligible for interferon-based therapy or cannot tolerate its side-effects, and await more effective interferon-free regimens.

Continue reading this entire article:
http://www.aidsmap.com/page/2514717/

No Comments - be the first!
Share
Share

Previous

New Phase 2 Paid Hepatitis C Clinical Trial

Back to News Homepage

Next

Urgent Reason for Hep C Patients to Get Lean!

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.